Margin-at-Risk Calculator
See how much buy-and-bill margin your infusion center is losing to documentation gaps — and what dropping denials to under 5% recovers.
Your Operation
Total active treatment chairs across your sites
Industry typical: 8–12 for biologics; higher for oncology/IVIG
Typical: 10–20% for biologic and specialty claims before optimization
CMS estimates 60–70% trace to eligibility, prior auth, or coding errors
Net margin after overhead and acquisition (typical: 5–10%)
Approximate mix — remainder is priced as blended "other infusibles". Demo ASP rates shown.
Remaining mix (10%) is priced as blended other infusibles ($3,500).
Adjust the assumptions — every factor is editable
The expected case uses the values below. Change anything — the math updates live.
Operating weeks used to annualize volume. Conservative case uses the same.
The conservative case recovers this share of the expected figure.
Flat rate, unlimited users
Preventable denial loss recovered (to a 5% floor)
Recovery is capped at BOTH the documentation-preventable share (65% of losses) AND the actual gap between your 14% denial rate and a 5% floor — whichever is smaller. No flat percentages.
Show the math
5-Year Projection
Interested in a custom ROI analysis for your specific operation?Contact our strategy team